UNICREDIT BANK/CALL/BIOGEN IDEC/320/0.1/19.03.25 | Real-time BOERSE MUENCHEN 12:42:06 13/06/2024 BST | ||
| 0.8 EUR | 0.00% |
|
| Current month | -1.23% | ||
| 1 month | +26.98% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
BIOGEN INC.
Latest news about BIOGEN INC.
More news
| Date | Price | Change |
|---|---|---|
| 13/06/24 | 0.8 | 0.00% |
| 12/06/24 | 0.8 | +8.11% |
| 11/06/24 | 0.74 | +1.37% |
| 10/06/24 | 0.73 | 0.00% |
| 07/06/24 | 0.73 | -17.05% |
Real-time BOERSE MUENCHEN
Last update June 13, 2024 at 12:42 pm
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | BIOGEN INC. |
| Issuer | 
UniCredit
|
| WKN | HD4FKS |
| ISIN | DE000HD4FKS9 |
| Date issued | 08/04/2024 |
| Strike | 320 $ |
| Maturity | 19/03/2025 (279 Days) |
| Parity | 10 : 1 |
| Emission price | 0.54 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 0.97 € |
|---|---|
| Lowest since issue | 0.31 € |
| Spread | 0.31 € |
| Spread % | 32.98% |
Company Profile
Biogen Inc. is one of the world's leaders in the design, manufacturing, and marketing of therapeutic products. Net sales break down by source of income as follows:
- sales of medicines (73,7%): for treating multiple sclerosis, chronic psoriasis in adults, rheumatoid arthritis, cancers, etc.;
- royalties (17,2%) ;
- other (9,1%): primarily revenues from partnership agreements.
Sector
-
Consensus: Biogen Inc.
Sell
Buy
Mean consensus
BUY
Number of Analysts
34
Last Close Price
230.6
USD
Average target price
284.6
USD
Spread / Average Target
+23.42%
- Stock Market
- Warrants
- Warrant
